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ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is the worst prognoses among all 
the malignancies. Now, gemcitabine (Gem) is the first line chemotherapeutic drug 
for advanced pancreatic cancer. However, Gem is usually ineffective to the PDAC 
because of high degree of drug resistance. Hypoxia and immune suppressive milieu 
are the best-described hallmarks of PDAC; therefore, we investigated the impact of 
hypoxia inducible factor-1 (HIF-1) inhibitor, PX-478, in combination with Gem on the 
induction of immunogenic cell death (ICD). We verified that combined treatment with 
Gem/PX-478 significantly enhanced the anti-tumor effect and increased proportion 
of tumor infiltrating T-lymphocytes in Panc02-bearing immune-competent but not 
in immune-deficient mice. Vaccination using Panc02 cell line treated with single 
agent or in combination showed significant anti-tumor effects. Pancreatic cell lines 
treated with Gem and PX-478 can induce an increase in eIF2α phosphorylation was 
correlated with down-regulation of HIF-1α and elicited exposure of CRT and release of 
HMGB1 and ATP. Only co-treated cells induced DC maturation/phagocytosis and IFN-γ 
secretion by cytotoxic T lymphocytes. Altogether, combined treatment with Gem/PX-
478 showed significantly inhibition on tumor growth and anti-tumor immunization. We 
propose that inhibition HIF-1α elicits Gem-induced immune response and eliminates 
PDAC cells by inducing ICD.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is one 
of the most aggressive human neoplasms, with an overall 
5-year survival rate of less than 5% [1]. Even the patients 
obtained radical resection and adjuvant chemotherapy, 
the 5-year survival rate is between 15 % and 25 % [2]. 
Compared to other malignancies, pancreatic cancer is 
highly resistance to chemotherapy and targeted therapy 
[3, 4]. Currently, the standard treatment for advanced 
pancreatic cancer is single-agent gemcitabine (Gem) [5]. 
However, the clinical effect of Gem remains modest due to 
an inherent and acquired chemo-resistance [6]. Therefore, 
new treatment strategies are urgently needed to improve 
the prognosis of patients with PDAC.
We have previously demonstrated that hypoxia-
inducible factor-1α (HIF-1α) plays crucial roles in the 
pathogenesis and progression of pancreatic cancer [7, 
8]. Initially identified as a critical transcription factor 
mediating cell adaption to hypoxia [9], it was recently 
found that HIF-1α is overexpressed in pancreatic cancer 
even under normoxia condition and levels of HIF-
1α are positively correlated with tumor progression, 
angiogenesis, cell migration and poor prognosis [7, 
8, 10, 11]. Therefore, inhibition of HIF-1α expression 
could be a therapeutic target to control this aggressive 
disease. Importantly, it was reported that HIF-1α is highly 
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expressed in Gem-resistant pancreatic cancer cells and 
this is associated with epithelial-mesenchymal transition 
of cancer cells [12], suggesting that inhibition of HIF-1α 
may have potential to overcome the resistance of PDAC 
cells to the treatment with Gem. PX-478 (S-2-amino-3-
[4V-N,N,-bis(2-chloroethyl) amino]-phenyl propionic 
acid N-oxide dihydrochloride) is a specific agent that 
suppresses constitutive and hypoxia-induced levels of 
HIF-1α in cancer cells [13, 14]. Recent clinical trials have 
shown that PX-478 achieved a relatively high disease 
control ratio in the treatment of advanced cancer and 90% 
of patients were well tolerated to the reagent (Phase I Trial 
of PX-478, NCT00522652). Thus, combination of Gem 
with PX-478 may have a potential strategy to improve the 
efficacy of Gem therapy in patients with pancreatic cancer.
In order to achieve effective treatment, 
chemotherapy should improve anti-cancer immunity 
and alleviate intra-tumoral immunosuppression [15, 
16]. Recently, immunogenic cell death (ICD) has 
been considered as the best way to induce an adaptive 
immune response and improve the efficacy of anti-
cancer treatment [17-19]. ICD is a cell death modality 
that stimulate an immune response against dead-cell 
antigens and is featured by (1) the dying cell exposure 
of damage-associated molecular patterns (DAMPs) 
including calreticulin (CRT) and/or heat shock proteins 
(HSPs) in pre- or early apoptotic stages; (2) the pre- or 
early apoptotic secretion of ATP; and (3) the late apoptotic 
passive release of non-histone chromatin protein high 
mobility group box 1 (HMGB1) and possibly of HSP70 
and HSP90 [18-20]. DAMPs exposure leads to the specific 
recognition by antigen presenting cells (APCs), i.e., 
dendritic cells (DCs) and macrophages, which become 
mature and prime the tumor specific T and natural killer 
(NK) cells to react against tumor cell antigens [21, 22].
There is limited information on which 
chemotherapeutic agents can induce ICD in pancreatic 
cancer. The capacity of Gem on inducing ICD in 
PDAC is currently debated [23, 24] and it may require 
a complementary approach to trigger this process [24]. 
Numerous reports demonstrated that inhibition of HIF-1α 
could overcome resistance of tumor cells to chemotherapy 
[25, 26]. Recently, it has been proposed that inhibition of 
HIF-1α could be a complementary approach for cancer 
immunotherapy [27]. However, whether HIF-1α inhibitors 
could promote ICD has not been defined. 
In our own studies, we have found that HIF-
1α is overexpressed in patients with PDAC [7, 8]. We 
hypothesize that inhibition of HIF-1α could enhance 
the therapeutic efficacy of Gem. In this study, we aimed 
to compare the efficacies of PX-478 (a specific HIF-
1α inhibitor) and chemotherapy drug Gem, as a single 
agent or in combination, in inducing anti-tumor immune 
response and immunogenic elimination of PDAC tumor 
in immune-competent and immune-deficient PDAC-
engrafted mice. Gem and/or PX-478-induced ICD 
markers and immune response, including DC maturation/
phagocytosis, and activity of cytotoxic T-cells were 
determined accordingly in vitro.
RESULTS
PX-478 enhances the therapeutic efficacy of Gem 
only in the immune-competent mice models 
In vitro experiments showed that inhibition of 
HIF1α by PX-478 sensitized PDAC cells lines to GEM 
induced apoptosis (data not shown). To evaluate the 
antineoplastic effects of this combination in vivo, we 
implanted Panc02 cells in immune-competent C57BL/6 
and immune-deficient nude mice and treated them with 
Gem and/or PX-478. Gem or PX-478 alone significantly 
reduced tumor growth in both immune-competent and 
incompetent mice (Figure 1) and there was no significant 
difference when either single treatment efficacy was 
compared between two mice models. When Gem 
combined with PX-478, the tumor suppression effect of 
Gem or PX-478 was significantly increased in immune-
competent in C57BL/6 mice (Figure 1A, B and C) but 
not in nude mice (Figure 1 D, E and F) compared with 
treated with Gem alone. This suggests that the therapeutic 
efficacy of this combined treatment with Gem and PX-
478 may depend on the presence of thymus-dependent T 
lymphocytes because it was deficient in nude mice. These 
results indicate that Gem and PX-478 combination may 
induce a tumor antigen-specific immune response which 
in turn elicits elimination of tumor cells.
Combination of PX-478 with Gem significantly 
increases the vaccine efficacy compared with 
single treatment
To further confirm whether Gem plus PX-478 (Gem/
PX-478) combination can elicit immune response, we 
vaccinated immune-competent C57BL/6 mice with Panc02 
cells which were treated with Gem, PX-478 or Gem/PX-
478. After one week, the mice were challenged on the 
other flank with live Panc02 cells. None of the C57BL/6 
mice developed tumors on the vaccinated flank. All the 
mice in the non-immunized group developed tumors at 
the challenge site and died within 17 days. Either Gem or 
PX-478-immunized group showed significantly reduced 
tumor volumes (P<0.001) compared with non-vaccinated 
group and died within 25 days. Most strikingly, Gem/PX-
478-immunized mice showed significantly reduced tumor 
volumes (P<0.001), and 5 in 8 of mice were alive at 60 
days post challenge (Figure 2A, B and C). The survival 
rate was significantly increased in the Gem/PX-478 group 
(P<0.001) (Figure 2D). These results demonstrate, for the 
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Figure 2: Vaccination impact of Gem/PX-478 on tumor growth in C57BL/6 mice. Panc02 cells were in vitro incubated with 
saline, Gem (1.0 μM), PX-478 (25 μM) or both of them for 24 hours. Dying and dead cells/supernatant were subcutaneously injected into 
C57BL/6 mice (8 mice/group). After 7 days live Panc02 cells were inoculated on the other flank. (A) Image of tumor-bearing mice. (B) 
Tumors separated from mice. (C) Time-dependent tumor growth. Tumor growth was evaluated by measuring tumor volumes and compared 
statistically by Two-way ANOVA with Bonferroni post-hoc test. (D) Kaplan-Meier curve of survival rates. Tumor growth was compared 
using the log-rank test, illustrated with Kaplan–Meier curves. ***P<0.001 indicates comparison of tumor growth between control group 
with Gem, PX-478 or Gem/PX-478 groups. 
Figure 1: Therapeutic effects of Gem and/or PX-478 in immune-competent and immune-deficient mice. Murine PDAC 
cell line Panc02 was inoculated into the right flank of C57BL/6 mice (7 mice/group) and nude mice (5 mice/group) and subsequently treated 
with saline (control), Gem (i.p at 15 mg/kg on days 1, 3, 5 every week) and PX-478 (p.o. gavage at 30 mg/kg ×2 consecutive days) and Gem 
plus PX-478. (A and B) Representative images of tumors formed in C57BL/6 mice. (D and E) Representative images of tumors formed in 
nude mice. (C and F) Statistical comparisons of tumor volumes in C57BL/6 (C) and nude mice (F). Time-dependent tumor growth of treated 
groups was analysed by Two-way ANOVA with Bonferroni post-hoc test by comparison with untreated group or Gem/PX-478 treated 
group compared with single treatment. ***P<0.001. NS indicates no significance. 
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first time, that Gem/PX-478 combination has high vaccine 
efficacy against tumor growth via inducing immunogenic 
cell death. 
Combination of Gem with PX-478 increases 
infiltrating T cells in tumor-bearing C57BL/6 mice
We then hypothesised that the pro-survival effect of 
Gem/PX-478 co-treatment may be due to immunogenic 
elimination of tumor cells. T lymphocytes from peripheral 
blood, spleen and tumor of C57BL/6 mice were purified 
and determined by flow cytometry. The proportions of 
CD3+ and CD8+ cytotoxic T lymphocytes in Gem/PX-
478 group were not significantly increased in peripheral 
blood compared with treated with either Gem or PX-478 
group (Figure 3A and B). However, significantly increased 
cytotoxic CD3+/CD8+ T lymphocytes were detected in 
spleen (Figure 3C and D) and tumor tissues (Figure 3E and 
F) in mice treated with Gem/PX-478 compared with single 
treatment (Figure 3 and Suppl Figure 1). Collectively, the 
data suggest that chemotherapy with Gem/PX-478 may 
eliminate tumor cells by tumor-infiltrating cytotoxic T 
lymphocytes-mediated ICD.
Figure 3: Determination of cytotoxic CD3+ and CD8+ T lymphocytes. Panc02 cells were inoculated into the right flank of 
C57BL/6 mice (7 mice/group) and subsequently treated with Saline, Gem (i.p at 15 mg/kg on days 1, 3, 5 every week), PX-478 (p.o. 
gavage at 30 mg/kg ×2 consecutive days), or Gem/PX-478. The proportion of CD3+ and CD8+ T cells isolated from peripheral blood (A), 
spleen (B), or tumor (C) were analysed by flow cytometry. Statistical significance was analysed by two-tailed Student’s t-test. Significantly 
increased T cells in Gem/PX-478 treated group were compared with treated with Gem or PX-478 alone (n=7). * indicates P<0.05, ** 
indicates P<0.01 and ‘NS’ means no significance.
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Inhibition of HIF-1α sensitizes PDAC cells to Gem 
or OXP-induced phosphorylation of eIF2α 
We questioned whether the sensitization effect 
of PX-478 on ICD inducers is due to inhibition of HIF-
1α. Induction of surface exposure of CRT (ecto-CRT) is 
one of the hallmarkers of ICD [28-30] and it occurs as 
a consequence of ER stress-induced phosphorylation 
of eIF2α [18, 19, 31]. Ecto-CRT was stained on non-
permeabilized cells which had been treated individually 
as indicated. Gem or PX-478 alone had weaker effect on 
triggering CRT exposure but treatment with Gem/PX-
478 showed strong induction of CRT surface exposure 
(Figure 4A). To determine the association between HIF-
1α inhibition and eIF2α phosphorylation, treatment-
induced alterations of HIF-1α, CRT, P-eIF2α and eIF2α 
protein expression were monitored in 5 PDAC cell lines. 
A typical ICD inducer, OXP (oxaliplatin) [18, 19] was 
used as a positive control. While none of these reagents 
induced changes in CRT and eIF2α expression, all of them 
mediated down-regulation of HIF-1α and up-regulation of 
P-eIF2α. Combination of PX-478 with either Gem or OXP 
led to maximum inhibition of HIF-1α and up-regulation 
of P-eIF2 α (Figure 4B). Treatment-induced changes in 
HIF-1α and P-eIF2α showed strong negative correlation, 
P<0.01, γ=-0.943 (Figure 4C). To further evaluate the 
effect of HIF-1 inhibition on ICD, PDAC cells were either 
transfected with HIF-1α-siRNA or treated with another 
HIF-1α inhibitor 2-Methoxyestradiol (2-ME) (Selleck. 
cn). As expected, both HIF-1α-siRNA and 2-ME induced 
eIF2α phosphorylation in PDAC cells (Figure 4D). These 
results demonstrate that inhibition of HIF-1α expression 
could trigger ICD by up-regulation P- eIF2α. 
Co-treatment with PX-478 enhances 
chemotherapy-induced HMGB1 and ATP release
Release of HMGB1 and ATP from dying or dead 
cells are also crucial hallmarkers of ICD [18-20]. HMGB1 
release from nucleus was determined by both immuno-
fluorescent microscopy (Figure 5A) and Western blotting 
(Figure 5B). In control cells, HMGB1 is mainly expressed 
Figure 4: Negative correlation between HIF-1α expression and eIF2α phosphorylation. PDAC cell lines were incubated 
with saline, Gem (1.0 μM), PX-478 (25 μM), Gem/PX-478, OXP (oxaliplatin) (300μM) or OXP/PX-478 for 24 hours. (A) CRT surface 
exposure on CFPAC-1, BxPC-3 and Panc02 cell lines. Non-permeabilized cells were co-stained with anti-CRT antibody and Hoechst 
33342 and determined by confocal microscopy (magnification, 600×). Green colour indicates ecto-CRT. (B) Five PDAC cell lines were 
treated with GEM, PX-478, OXP (300μM), Gem/PX-478, or Gem/OXP for 24 hours. Expression of HIF-1α, CRT, P-eIF2α, and eIF2α was 
determined by Western blotting. β-tubulin was used as a loading control and OXP was served as a positive control. (C) Negative correlation 
between levels of HIF-1α and P-eIF2α. Expression levels of both HIF-1α and P-eIF2α were analysed by densitometry and represented as 
ratios of HIF-1α/β-tubulin and P-eIF2α/β-tubulin. Data were collected from 5 cell lines and expressed as mean ± SD. Correlation between 
HIF-1α and P-eIF2α was analysed by Pearson’s correlation method. **P<0.01, γ=-0.943. (D) Pancreatic cancer cell lines (CFPAC-1 and 
BxPC-3) were treated with siHIF-1 and 2-ME and then evaluate the expression HIF-1α, CRT and P-eIF2α by Western blotting experiment.
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in the nucleus. Treatment with either Gem or PX-478 alone 
induced a translocation of HMGB1 from the nucleus to the 
cytoplasm. Co-treatment with Gem/PX-478 caused a loss 
of HMGB1 in the nucleus (Figure 5A). Western blotting 
confirmed that treatment with Gem/PX-478 induced 
maximum HMGB1 release compared with other treatment 
(Figure 5B). Similarly to HMGB1 release, Gem/PX-478 
induced a significantly increased ATP release (P<0.001) 
in all 5 PDAC cell lines compared with other groups 
(Figure 5C). In summary, these data demonstrate that in 
the presence of HIF-1α inhibitor PX-478, GEM gains its 
ICD-inducing potential on triggering the exposure and 
release of ICD markers in pancreatic cancer cells.
Conditioned medium or killed PDAC cells 
enhances immune response of DC and T cells 
To test whether ICD markers in the conditioned 
medium could enhance immune response, human 
immature dendritic cells (iDCs) (treated with GM-CSF 
and IL-4 for 5 days) were incubated with conditioned 
supernatants from Gem or Gem/PX-478 treated cells for 
another 24 hours. Maturation of DCs was determined 
by expression of CD80 or CD83 using flow cytometry. 
Treatment with Gem/PX-478 significantly increased 
expression of both CD83 (Figure 6A) and CD80 (Figure 
6B), indicating of maturation of DCs. To determine the 
phagocytosis single of ecto-CRT, iDCs (treated with GM-
CSF and IL-4 for 5 days) were co-cultured with pancreatic 
cancer cells treated with saline, Gem, PX-478, or Gem/
PX-478 for 24 hours. And then, fluorescence microscopy 
was used to evaluate the phagocytosis of DCs. DCs 
activated with Gem/PX-478-treated cells showed more 
phagocytosis activity compared with single treatment, as 
shown by double positive, or yellow coloured cells (Figure 
6C). Most importantly, the co-culture Gem/PX-478 
condition medium challenged DCs with autologous CD3+/
CD8+ T cells significantly increased the secretion of IFN-γ 
by cytotoxic T-cells compared with control and those 
treated with single agent (Figure 6D). Taken together, 
these data confirmed that conditioned supernatants of 
Figure 5: HMGB1 and ATP release in response to treatment. PDAC cell lines were incubated with saline, Gem (1.0 μM), PX-
478 (25 μM), or Gem/PX-478, OXP (oxaliplatin) (300μM) or OXP/PX-478 for 24 hours. (A) Determination of treatment-induced HMGB1 
re-localization and release in three PDAC cell lines by fluorescent microscopy (magnification, 1000×). After treatment, cells on slides 
were fixed/permeablized and stained with both mouse anti-HMGB1 antibody/Alexa Fluor 568-conjugated secondary anti-mouse antibody 
(showing red) and DAPI (showing blue). (B) Determination of treatment-induced HMGB1 release in five PDAC cell lines by Western 
blotting. After treatment, 50 µl of conditioned medium was taken for detecting HMGB1 in the supernatants. (C) Chemiluminescence 
detection of treatment-induced ATP release in five PDAC cell lines. After treatment, 10 µl of conditioned medium was taken for ATP assay 
using chemiluminescence ELISA kit. Significantly increased ATP release by Gem/PX-478 (***P<0.001) was compared with those treated 
with single agent. 
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Gem/PX478-treated PDAC cells can enhance immune 
response by inducing maturation and phagocytosis of DCs 
and up-regulate cytotoxic function of T cells.
DISCUSSION
PDAC is highly resistant to both conventional 
and targeted chemotherapy. Increased numbers of 
circulating regulatory T cells, myeloid-derived suppressor 
cells and tumor-associated macrophages in the PDAC 
microenvironment suppress immune surveillance and 
dampen anti-tumor immune responses [32, 33]. Here we 
demonstrate, for the first time, that inhibition of HIF-1α 
expression by PX-478 enhances immunogenicity of Gem 
and elicits tumor-specific DC phagocytic and cytotoxic T 
cell responses to PDAC cells. 
Although Gem is currently used as a first-line 
chemotherapeutic drug for advanced pancreatic cancer, it 
has only a 5.4% partial response rate and most patients 
do not respond well to single agent Gem and almost 
all the patients finally develop drug resistance [34]. 
Immunosuppression-induced by tumor microenvironment 
is one of the causes of failure in response to the treatment 
with Gem [33]. To promote the therapeutic effect of Gem, 
one rational approach is to combat drug-resistance by 
inducing ICD. 
HIF-1α is an important transcription factor for tumor 
growth, invasion, angiogenesis, metabolism and drug 
resistance [7, 10, 25]. Typically, Gem-resistant pancreatic 
cancer cells overexpress HIF-1α that mediates acquired 
drug tolerance and tumor progression [12, 35]. Therefore, 
inhibition of HIF-1α would be a promising therapeutic 
strategy to strengthen the efficacy of Gem. We initially 
found that inhibition of HIF-1α by PX-478 increased 
the sensitivity of PDAC cells to Gem-induced apoptosis 
in vitro (data not show). Indeed, combination with PX-
478 significantly increased inhibitory effect of Gem on 
Figure 6: Comparison of treatment-induced immune response in both DCs and cytotoxic T cells. (A and B) DC maturation. 
DCs were stimulated with conditioned supernatant of freeze/ thawed, PX-478, Gem or Gem/PX-478 treated cell culture medium. The 
maturation markers for DCs, CD83 or CD80, were evaluated by flow cytometry and compared between freeze/ thawed, PX-478, Gem and 
Gem/PX-478-treated groups. **P<0.01. Data were expressed as mean ± SD and each value represented the mean of three replicates. (C) 
Fluorescence microscopy analysis of phagocytosis. After 24 hours co-culture of immature DCs with killed tumor cells, the engulfment of 
tumor cells was verified by fluorescence microscopy. DCs were stained with DiO (green) and CFPAC-1 cells were stained with DiI (red). 
Double positive or yellow cells are fully phagocytized cells. (D) IFN-γ production. Immature DCs were pulsed with killed tumor cells for 
24 hours and then co-cultured with autologous CD3+/CD8+ T lymphocytes. IFN-γ concentration in the supernatant was assessed after 10 
days using the IFN-γ ELISA kit. A representative out of three independent experiments is depicted. ***P<0.001.
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tumor growth in PDAC-engrafted immune-competent 
mice. However, PX-478 did not improve the efficacy of 
Gem in an immune-deficient mice model. To confirm the 
immunogenic effect of this combination, we vaccinated 
treatment-induced dead cells to immune-competent mice 
and found that cells treated with Gem/PX-478 showed 
greater effect on eliminating tumor cells compared with 
vaccinated with cells treated with single agent. Most 
strikingly, more than half of mice after challenged with 
Gem/PX-478-treated cells reached long-term survival 
(60 days), indicating that the dead cell antigens-mediated 
by Gem/PX-478 can enhance immune surveillance and 
trigger anti-tumor immune response. As expected, we 
found significantly increased cytotoxic infiltrating T cells 
in both spleen and tumor tissues in Gem/PX-478-treated 
mice compared with those treated with single agent. PX-
478 elicited immunogenicity on Gem was also confirmed 
by in vitro experiments. Conditioned medium from Gem/
PX-478-treated PDAC cells triggered DC maturation 
and tumor-specific phagocytosis capacity and activation 
of tumor-specific cytotoxic T-cells but those treated with 
single agent showed minimum immunogenicity. These 
results indicate that either Gem or PX-478 is not ICD 
inducer but Gem obtained immunogenic potential when 
HIF-1α is inhibited. 
We were interested in whether these treatment 
strategies could act differently in inducing ICD markers 
on tumor cells. Similar to immune responses, Gem/PX-
478 showed higher potential in inducing CRT surface 
exposure, ATP and HMGB1 release compared with 
single treatment. It is known that CRT translocation from 
endoplasmic reticulum (ER) to the out-layer of plasma 
membrane depends on an ER stress and associated with 
ER kinase (PERK)-mediated eIF2α phosphorylation [18, 
19]. We found that PX-478 induced HIF-1α inhibition 
is negatively correlated with eIF2α phosphorylation. To 
verify whether this effect on eIF2α phosphorylation is 
specifically due to inhibition of HIF-1α, we confirmed 
this phenomenon by using other HIF-1α inhibitor (2-
ME) and HIF-1α-siRNA as well. Our results suggest that 
HIF-1α pathway might inhibit ER stress and subsequent 
CRT exposure. It has been reported that the ER stress is 
a consequence of production of reactive oxygen species 
(ROS) [36] and HIF-1α can decrease ROS production by 
reprogramming glucose metabolism [37]. We postulate 
that inhibition of ROS production by HIF-1α might be 
a possible mechanism to reduce ER stress. PX-478 also 
significantly enhanced Gem-induced ATP release. The 
function of ATP is to recruit monocytes and macrophages 
to the dying tumor cells and stimulate secretion of 
IL-1β, a key cytokine to polarize interferon-gamma-
producing CD8+ T cells [38]. In addition, we observed 
reduction of HMGB1 from nuclear extracts of PX-478-
treated cells and concomitant accumulation of HMGB1 
in the conditioned medium. HMGB1 is a nuclear protein 
mediating stabilization of nucleosomes, DNA repair and 
recombination. Extracellular HMGB1 is required for the 
immunogenicity of ICD. It binds to the Toll-like receptor 
Figure 7: Combinatorial immunochemotherapy based on immunogenic cell death induced by Gem and PX-478 
exerting synergistic anticancer activity. Pancreatic cancer cells treated with Gem and PX-478 directly provoke an endoplasmic 
reticulum (ER) stress, leading to the release of damage-associated molecular patterns (DAMPs) within the tumor microenvironment 
(surface exposure of CRT (ecto-CRT), ATP secretion and HMGB1 release). DAMPs exposure leads to the specific recognition by antigen 
presenting cells (APCs), i.e., dendritic cells (DCs) and macrophages, which become mature and prime the tumor specific T and natural 
killer (NK) cells to react against tumor cell antigens. In sum, the combined administration of Gem and PX-478 might activate synergistic 
immunological response culminating in improved anticancer immune responses. 
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4 (TLR-4) on the surface of DC and mediates cross-
presentation efficiency [39]. We postulate that plasma 
HMGB1 concentration after treatment could also be used 
as a marker for predicting therapeutic response to Gem/
PX-478 in patients with pancreatic cancer. 
In recent years, new combination chemotherapeutic 
strategies gained better clinical benefit compared with 
single-agent Gem in pancreatic cancer. In 2011, the 
ACCORD-11/PRODIGE-4 trial (a multicenter randomized 
control phase III trial) confirmed that FOLFIRINOX 
(fluorouracil, leucovorin, irinotecan, and oxaliplatin) 
significantly prolonged the overall survival of patients 
with metastatic pancreatic cancer, compared with gem 
along (11.1 vs 6.8 months), although the safety profile of 
FOLFIRINOX was not as favourable as that of single-
agent Gem [40]. In 2013, Gem plus nab-paclitaxel 
achieved better overall survival (median: 8.5 month 
vs 6.7 month) compared with Gem alone, based on a 
multinational phase III trial. Soon, the FDA approved Gem 
plus nab-paclitaxel as a first line treatment for patients 
with pancreatic cancer. Based on these achievements, 
combination of GEM and PX-478 provides a promising 
strategy to kill pancreatic cancer and need to be enrolled 
for clinical trials. 
In conclusion, this study verified by both in vivo and 
in vitro experiments that combination of Gem with PX-
478 effectively inhibited tumor growth by inducing ICD in 
pancreatic cancer. Gem/PX-478-mediated immunogenicity 
is dependent on eIF2α phosphorylation-associated CRT 
surface exposure, increased ATP and HMGB1 release. 
HIF-1α inhibition plays a key role in this sensitization 
on immune responses. Most importantly, we found that 
vaccination using Gem/PX-478-treated cells has great 
potential to prevent tumorigenesis. 
MATERIALS AND METHODS
Cell lines, cell culture and in vitro treatment
Human PDAC cell lines CFPAC-1, BxPC-3, Panc-
1, and MIA-PaCa-2 were obtained from the Cell Bank of 
Type Culture Collection of Chinese Academy of Sciences 
(Shanghai, China) and the American Type Culture 
Collection, respectively. The murine pancreatic cancer 
cell line Panc02 [41] was a gift from Prof. Yang SY. Cell 
lines were routinely cultured at 37 °C in a humidified 
atmosphere of 95% air and 5% CO2 using Dulbecco’s 
modified Eagle medium (DMEM) with 10% fetal bovine 
serum (FBS). For in vitro treatment, 5 × 105/ml cells in 
6-well plate were treated with 1.0 μM Gem (Eli Lilly, 
Fegersheim, France) [24], or/and 25 μM PX-478 (MedKoo 
Biosciences, Inc, USA) [10, 42] for 24 hours in the routine 
culture condition. Cell death was determined by flow 
cytometry on Annexin-V/propidium iodide positive cells.
Chemotherapy of established tumor in mice 
All mice were maintained in specific pathogen-free 
conditions and the animal experiment procedures were 
approved by the Ethics Committee of Tianjin Medical 
University Cancer Institute and Hospital. Immuno-
competent 4-week-old female C57BL/6 mice and 
immuno-incompetent nude (Nu/Nu) mice were injected 
subcutaneously in the flank with 1×106 Panc02 cells. The 
tumor volumes were monitored every five days using 
digital callipers. When the tumor size reached 40-80mm3, 
mice were assigned into homogenous groups and treated 
with Gem (i.p at 15 mg/kg on days 1, 3, 5 every week) [6] 
or/and PX-478 (p.o. gavage at 30 mg/kg × 2 consecutive 
days) [42]. Tumor volumes were calculated using the 
formula π/6 [(short axis in mm)2 × (long axis in mm)] for 
comparison of tumor growth [43]. 
Determination of peripheral and infiltrating CD3+ 
and CD8+ T lymphocytes 
Tumor-bearing animals were euthanized by cervical 
dislocation as soon as they presented signs of necrosis. 
Peripheral blood was collected from the mice and spleen 
cell suspensions were produced by forcing the spleen 
through a wire mesh screen. Tumor single-cell suspension 
was prepared from tumor by digesting and mechanically 
dissociating with a MACS Dissociator (Miltenyi Biotec, 
Germany), followed by filtration through a 70-mm nylon 
mesh [44]. Cells were then co-stained with PE-anti-CD3 
and APC-anti-CD8 antibodies (Biolegend, USA). Surface 
expression of CD3 and CD8 were determined by flow 
cytometry (BD FACS Canto II, BD, USA). 
Anti-tumor vaccination
A total of 3×106 Panc02 cells, untreated or treated 
with either Gem and/or PX-478 for 24 hours, dying and 
dead cells/supernatant were inoculated subcutaneously 
into 6-week-old female C57BL/6 mice into the right flank, 
whereas 1×106 untreated Panc02 cells were inoculated into 
the contralateral flank 7 days later [45, 46]. Animals that 
bore tumors in excess of 20–25% of the body mass or 
were necrotic, were euthanized. 
Western blotting 
Whole-cell extracts were prepared by lysing cells 
with RIPA lysis buffer supplemented with protease 
inhibitor cocktails (Sigma). Protein concentrations were 
quantified using Pierce protein assay kit (Pierce). Cellular 
protein lysates (20 μg) were separated by 10% SDS-PAGE, 
and target proteins were detected by Western blotting 
using primary antibodies against CRT, HIF-1α, HMGB1, 
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eIF2α, phosphorylated eIF2α (P-eIF2α), and β-tubulin 
(Suppl Table 1). Specific proteins were visualized using an 
enhanced chemiluminescence detection reagent (Pierce). 
For determining HMGB1 release, 50 µl of conditioned 
culture medium was loaded into each lane of SDS-PAGE 
gel and extracellular HMGB1 was detected by Western 
blotting using an anti-HMGB1 antibody [47]. 
Preparation of human DCs and T lymphocytes
Human peripheral blood mononuclear cells 
(PBMCs) were isolated from healthy donors by Ficoll-
Hypaque (Solarbio Co., China) density gradient 
centrifugation and cultured in RPMI 1640 medium 
containing 10% FBS for 2 hours. DCs were generated 
from the adherent fraction of PBMCs [48]. The adherent 
cells were cultured for 6 days in RPMI 1640 medium 
containing 10% FBS, 20 ng/mL human GM-CSF, and 10 
ng/mL human IL-4 (Biolegend, USA). Culture medium 
and cytokines were refreshed every other day. On the day 
6, the medium was replaced by the Gem or/ and PX-478-
treated conditioned medium or control medium and cell 
culture was continued for 24 hours. Autologous CD3+ 
T lymphocytes were magnetically isolated using CD3 
MicroBeads (Miltenyi Biotech, Germany) to obtain purity 
≥95% CD3+ T cells. The isolated T lymphocytes were 
cultured in RPMI 1640 medium containing 10% FBS and 
10 ng/mL human IL-2 (Biolegend, USA), and the medium 
was replaced every other day.
Immunostaining and fluorescent microscopy
The surface exposure of CRT was determined by 
immunostaining as previously described [28]. Briefly, after 
treatment cells were washed twice with PBS and fixed in 
0.25% paraformaldehyde in PBS for 5 min. Cells were 
then washed with PBS for three times. The rabbit anti-
calreticulin antibody (Cell Signaling Technology) was 
diluted in 3% BSA containing blocking buffer at 1:200 
dilution and cells were stained with it overnight at 4°C. 
After washes in cold PBS, cells were stained with Alexa 
Fluor 488-conjugated secondary anti-rabbit antibody (Life 
technologies, USA) at 1:500 dilution for 30 min at room 
temperature. Nuclei were stained with Hoechst 33342 
before images were viewed under OLYMPUS fluorescent 
microscope (Japan). 
For determining intracellular HMGB1, cells on 
slides were fixed with 4% paraformaldehyde for 20 min 
and permeabilized with 0.1% Triton X-100 for 10 min. 
Nonspecific binding was blocked with 3% BSA in PBS 
for 30 min. Cells were stained with mouse anti-HMGB1 
antibody (Sigma-Aldrich) at 1:100 dilution overnight at 
4°C. Subsequently, cells were washed three times with 
PBS and incubated with Alexa Fluor 568-conjugated 
secondary anti-mouse antibody (Life technologies) for 30 
min at room temperature in the dark [46]. Nuclei were 
stained with DAPI and HMGB1 localization was observed 
by fluorescent microscopy. 
The anti-tumor phagocytic function of matured 
DCs was assessed after DCs or tumor cells were labelled 
fluorescently with VybrantTM DiO (V-22886) or DiI 
(V-22885) cell-labelling solutions (Life technologies), 
respectively. Briefly, tumor cells were treated with Gem 
or/and PX-478 for 24 hours after stained with DiI (1:200 
dilution). DiO-loaded immature DCs (Day 5) were then 
fed with treated tumor cells at a DC/tumor cell ratio of 5:1. 
After incubation for 24 hours, the cells were fixed with 4% 
paraformaldehyde for 20 min, washed in PBS for 20 min 
and mounted on slides [49] and viewed under a fluorescent 
microscope. Double positive cells were considered as fully 
phagocytosed cells. 
ATP release assay
ATP concentration in the culture medium was 
performed using an ATP Determination Kit (Life 
technologies) according to the manufacturer’s instructions. 
Cell numbers were set up as 1 × 106/ml for all experiments. 
After treatment for 24 hours, 10 µl of conditioned medium 
was taken out for ATP assay. 
IFN-γ production
IFN-γ secretion from CD3+ T lymphocytes was 
assessed by IFN-γ ELISA Kit (Uscn Life Science Inc, 
China) according to the manufacturer’s instructions. 
RNA interference and cell transfection
Small interfering RNAs (siRNAs) against HIF-
1α (Suppl Table 1) was designed and synthesized from 
GenePharma (Shanghai, China). Cells were transfected 
with HIF-1α-siRNA using Lipofectamine 2000 (Life 
Technologies) and knocking-down effect of HIF-1α was 
determined by Western blotting after 48 hours.
Statistical analysis
Statistical analysis was performed using IBM SPSS 
version 18.0 for windows and GraphPad Prism software 
(version 5.03). For all in vitro experiments, at least 3 
independent experiments were performed. For in vivo 
experiments, 5 to 8 mice were used for each group/per 
experiment. Data are expressed as mean ± SD. Significant 
difference between two groups with equal numbers were 
analysed by two-sided Student t-tests and those with 
unequal sizes were analysed with the Mann-Whitney U 
test. Two-way ANOVA with Bonferroni post-hoc test was 
used to compare restriction of tumor cell growth in vivo 
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[50]. Kaplan-Meier survival curved were analyses using 
two-sided log-rank tests . Correlation between two groups 
of variables were analysed with Pearson correlation. All 
P-values <0.05 were considered as statistically significant.
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